When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Ares Capital (ARCC) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Hercules Technology Growth Capital makes loans to emerging technology businesses. Ares Capital offers a unique suite of financial products to lower-middle-market businesses.
Ares Capital (ARCC) closed the most recent trading day at $20.70, moving -0.72% from the previous trading session.
In the latest trading session, Ares Capital (ARCC) closed at $20.85, marking a -1.04% move from the previous day.
Recently, Zacks.com users have been paying close attention to Ares Capital (ARCC). This makes it worthwhile to examine what the stock has in store.
Bristol Myers Squibb's earnings outlook revision was disturbing but hardly a reason to avoid the Big Pharma stock. With a yield above 10%, PennantPark Floating Rate Capital is hard for income-seeking investors to ignore.
Investors focused on dividend stocks for high yields will usually end up looking at mortgage real estate investment trusts (REITs) and business development companies (BDCs) because they offer extremely high yields. Mortgage REIT dividends tend to go down over time — so the trick to succeeding in these sectors is not buying and holding indefinitely.
Ares Capital (ARCC) reachead $21.15 at the closing of the latest trading day, reflecting a +0.24% change compared to its last close.
Pfizer's been raising its dividend payout for 15 years, and a heap of new products could help it continue the streak. The largest publicly traded business development company, Ares Capital offers investors a yield above 9% at recent prices.
The S&P 500 currently yields just 1.2%, a level that may not be suitable for most income investors. In this article, I present 2 higher yielding stocks that are either reasonably valued or undervalued. Both carry strong balance sheets, pay well-covered dividends, and have plenty of capacity for growth.
Okta and Celsius have seen healthy growth and have room to run. Ares Capital has a 20-year track record, and the stock is dirt cheap.